# Notification of Non-Substantial/Minor Amendments(s) for NHS Studies

This template **must only** be used to notify NHS/HSC R&D office(s) of amendments, which are **NOT** categorised as Substantial Amendments.

# If you need to notify a Substantial Amendment to your study then you MUST use the appropriate Substantial Amendment form in IRAS.

#### Instructions for using this template

- For guidance on amendments refer to <a href="http://www.hra.nhs.uk/research-community/during-your-research-project/amendments/">http://www.hra.nhs.uk/research-community/during-your-research-project/amendments/</a>
- This template should be completed by the CI and optionally authorised by Sponsor, if required by sponsor guidelines.
- This form should be submitted according to the instructions provided for NHS/HSC R&D at <u>http://www.hra.nhs.uk/research-community/during-your-research-project/amendments/which-review-bodies-need-to-approve-or-be-notified-of-which-types-of-amendments/</u>. If you do not submit your notification in accordance with these instructions then processing of your submission may be significantly delayed.

#### 1. Study Information

Full title of study:	Improving perioperative care through the use of quality data: Patient Study of the Perioperative Quality
	Improvement Programme
IRAS Project ID:	215928
Sponsor Amendment Notification number:	12
Sponsor Amendment Notification date:	21.01.19
Details of Chief Investigator:	
Name [first name and surname]	Professor Suneetha Ramani Moonesinghe
Address:	Professor SR Moonesinghe
	Centre for Perioperative Medicine
	Department for Targeted Intervention
	Division of Surgery and Interventional Science
	University College London
	Charles Bell House
	43-47 Foley Street
	London
Postcode:	W1W 7TS
Contact telephone number:	07956620717
Email address:	ramani.moonesinghe@nhs.net

#### **Details of Lead Sponsor:**

Partner Organisations:				
Health Research Authority, England	NIHR Clinical Research Network, England			
NHS Research Scotland	NISCHR Permissions Co-ordinating Unit, Wales			
HSC Research & Development, Public Health Agency, Northern Ireland				
Name:	Suzanne Emerton			
Contact email address:	uclh.randd@nhs.net			
Details of Lead Nation:				
Name of lead nation	England			
delete as appropriate				
If England led is the study going	Yes			
through CSP?				
delete as appropriate				
Name of lead R&D office:	Joint Research Office, UCL, London, WC1 E6BT			


### 2. Summary of amendment(s)

This template **must only** be used to notify NHS/HSC R&D office(s) of amendments, which are **NOT** categorised as Substantial Amendments. If you need to notify a Substantial Amendment to your study then you MUST use the appropriate Substantial Amendment form in IRAS.

No.	Brief description of amendment (please enter each separate amendment in a new row)	Amendment applies to (delete/ list as appropriate)		List relevant supporting document(s), including version numbers (please ensure all referenced supporting documents are submitted with this form)		R&D category of amendment (category A, B, C) For office use only
		Nation	Sites	Document	Version	
1	Change of PI at Royal Liverpool and Broadgreen Hospital from Dr Peter Delve to Dr Ben Lane	England	Royal Liverpool and Broadgreen Hospital			
2	Addition of new sites: East and North Hertfordshire Trust Mid Yorkshire Hospital NHS Trust Royal Free London NHS Foundation Trust West Suffolk NHS Foundation Trust Western Sussex Hospitals NHS Foundation Trust Warrington and Halton Hospitals NHS Foundation Trust	England				

## 3. Declaration(s)

- I confirm that the information in this form is accurate to the best of my knowledge and I take full responsibility for it.
- I consider that it would be reasonable for the proposed amendment(s) to be implemented.



Signature of Chief I	nvestigator:	
Print name:		SR MOONESINGHE
Date:	21.01.2019	

# Optional Declaration by the Sponsor's Representative (as per Sponsor Guidelines)

The sponsor of an approved study is responsible for all amendments made during its conduct.

The person authorising the declaration should be authorised to do so. There is no requirement for a particular level of seniority; the sponsor's rules on delegated authority should be adhered to.

• I confirm the sponsor's support for the amendment(s) in this notification.

Signature of sponsor's representative:

Print name:....

Post: .....

Organisation:....

Date:....